Back to Search
Start Over
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
- Publication Year :
- 2008
-
Abstract
- Purpose Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial. Patients and Methods We have monitored and analyzed the cytogenetic and molecular response to IM 400 mg/d in a cohort of 277 late chronic phase (LCP) patients who were resistant or intolerant to interferon-α and were observed for 48 to 79 months (median, 72 months). Results One hundred fifty-three patients (55%) achieved a complete cytogenetic response (CCgR). Seventy-seven percent of them were still in CCgR after 5 years. The rate of response loss did not increase over time. The 6-year progression-free survival and overall survival of these 153 complete cytogenetic responders were 90% and 91%, respectively. Molecular response was less than major in 21%, major in 78%, and complete in one patient only. Conclusion These data confirm that, in LCP the CCgR rate to IM is 50% to 60%, and show that CCgR is stable and is associated with a prolonged survival, even if leukemia continues to be molecularly detectable.
- Subjects :
- Male
Cancer Research
Time Factors
Messenger
Drug Resistance
Fusion Proteins, bcr-abl
Gastroenterology
Piperazines
80 and over
FAILURE
Prospective Studies
RNA, Neoplasm
Chronic
Prospective cohort study
Proto-Oncogene Proteins c-abl
BCR-ABL
MOLECULAR RESPONSE
Aged, 80 and over
Leukemia
CHRONIC MYELOGENOUS LEUKEMIA
Myeloid leukemia
Middle Aged
Prognosis
Survival Rate
Treatment Outcome
Oncology
Cohort
Benzamides
Proto-Oncogene Proteins c-bcr
Imatinib Mesylate
Female
medicine.drug
MESYLATE THERAPY
FOLLOW-UP
INTERFERON-ALPHA
SURVIVAL BENEFIT
BLAST CRISIS
MANAGEMENT
Adult
medicine.medical_specialty
Alpha interferon
Antineoplastic Agents
Aged
Drug Resistance, Neoplasm
Humans
Interferon-alpha
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pyrimidines
RNA, Messenger
COMPLETE CYTOGENETIC RESPONDERS (CCR)
Internal medicine
medicine
IMATINIB MESYLATE (IM)
Survival rate
business.industry
LATE CHRONIC PHASE (LCP)
Fusion Proteins
Imatinib
medicine.disease
Surgery
Imatinib mesylate
Neoplasm
RNA
BCR-ABL Positive
business
Chronic myelogenous leukemia
Myelogenous
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....a8e1101b4618cdc93fb0b9e3368aed16